Revenue
2021
2022
2023
2024
2025
Indivior Pharmaceuticals, Inc. (INDV)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.24B | $1.19B | $1.09B | $901.0M | $791.0M |
| Gross profit | $994.0M | $957.0M | $919.0M | $749.0M | $664.0M |
| Research & development | $97.0M | $107.0M | $116.0M | $74.0M | $52.0M |
| Operating expenses | — | $919.0M | $1.07B | $831.0M | — |
| Operating income | $262.0M | $38.0M | −$152.0M | −$81.0M | $213.0M |
| EBITDAderived | $272.0M | $54.0M | −$137.0M | −$65.0M | $228.0M |
| Net income | $210.0M | $7.0M | −$126.0M | −$44.0M | $205.0M |
| Basic EPSper diluted share | $1.68 | $0.05 | -$0.92 | -$0.32 | — |
| Diluted EPSper diluted share | $1.64 | $0.05 | -$0.92 | -$0.32 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026Form 4 · 10b5-1 | Heidbreder ChristianChief Scientific Officer | SellCommon Stock | 18.6K | $38.06 | $707.4K | 227.9K |
| Jun 8, 2026Form 4 · 10b5-1 | Preblick RyanChief Financial Officer | SellCommon Stock | 36.0K | $37.70 | $1.36M | 284.8K |
| Mar 13, 2026Form 4 | Ryan BarbaraDirector | BuyCommon Stock | 8 | $31.09 | $248.72 | 5.7K |
| Mar 9, 2026Form 4 | Ryan BarbaraDirector | BuyCommon Stock | 31 | $32.56 | $1.0K | 5.7K |
| Mar 6, 2026Form 4 | Kingsley Stuart ADirector | BuyCommon Stock | 940 | $31.87 | $30.0K | 5.6K |